Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Cash from Financing Activities (2023 - 2026)

ArriVent BioPharma has reported Cash from Financing Activities over the past 4 years, most recently at $54.9 million for Q1 2026.

  • Quarterly results put Cash from Financing Activities at $54.9 million for Q1 2026, up 711.85% from a year ago — trailing twelve months through Mar 2026 was $251.2 million (up 3158.65% YoY), and the annual figure for FY2025 was $203.1 million, up 8.83%.
  • Cash from Financing Activities reached $54.9 million in Q1 2026 per AVBP's latest filing, up from $34.7 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $185.6 million in Q1 2024 and bottomed at -$1.1 million in Q4 2023.
  • Median Cash from Financing Activities over the past 4 years was $6.8 million (2025), compared with a mean of $37.5 million.
  • Peak annual rise in Cash from Financing Activities hit 63036.36% in 2025, while the deepest fall reached 96.36% in 2025.
  • Over 4 years, Cash from Financing Activities stood at -$1.1 million in 2023, then surged by 105.2% to $55000.0 in 2024, then skyrocketed by 63036.36% to $34.7 million in 2025, then soared by 58.02% to $54.9 million in 2026.
  • Business Quant data shows Cash from Financing Activities for AVBP at $54.9 million in Q1 2026, $34.7 million in Q4 2025, and $86.5 million in Q3 2025.